summary: This multi-centre randomised double blind placebo controlled trial (BENEFIT) looked at patients with clinically isolated syndromes and two or more asymptomatic brain lesions and found that interferon slowed development of MS at the two-year time point. The trial continues to see if this benefit is sustained at five years.

authors: Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Pohl C, Sandbrink R.

source: Neurology. 2006 Aug 16; [Epub ahead of print]

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: